Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03893474
Other study ID # BALK1005
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 30, 2019
Est. completion date November 2022

Study information

Verified date September 2021
Source Moorfields Eye Hospital NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, randomised, multi-site clinical trial testing the non-inferiority of community optometry follow-up of participants with QnAMD over 12 months


Description:

Neovascular Age-Related Macular Degeneration (nAMD) is a common vision threatening condition affecting mainly patients over the age of 65. At some point during follow-up the disease becomes inactive in many cases and does not need more injections. The risk of a flare-up is high, however, and patients need to continue to be seen every month for a significant period of time. Hospital-based eye clinics are struggling to cope with current and expected workload for assessing and treating patients with nAMD. Transferring care of these patients to the community closer to home would ease the workload for hospital based clinics and offer a better experience of care to patients. This study will recruit 742 patients with nAMD who have reached this inactive phase of the disease. Half of the patients that want to take part will continue to have their follow-up appointments in the hospital eye clinics as usual. The other half, chosen by chance, will have follow-up visits every month in a community optometrist practice by trained optometrists. The research team will provide the training for community optometrists. The study will seek to show that the community based care is no less safe than hospital-based care. The study will also check what is the impact of this different way of offering care on the NHS budget and how the patients and practitioners perceive this. The study will involve several hospital eye clinics across the country and several community optometrist practices. Meetings will also be held with patients to discuss their priorities and needs when looking at how to set up the community based eye clinics. During meetings with patients in preparation for this research, they felt positively about the possibility to receive care closer to home.


Recruitment information / eligibility

Status Recruiting
Enrollment 742
Est. completion date November 2022
Est. primary completion date May 2022
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Participants receiving treatment in nAMD injection clinics, who have reached the agreed definition of disease quiescence - Informed consent - Aged > 55 years - Ability to perform study specific procedures Exclusion Criteria: - Significant media opacities (cataract, vitreous opacities) that would not allow good quality fundus imaging. - Diabetic retinopathy of severity worse than mild non-proliferative stage and with any degree of diabetic maculopathy - History of other causes of Choroidal Neovascularisation (myopic, angioid streaks, inflammatory, retinal dystrophies, secondary to Central Serous Chorioretinopathy, idiopathic).

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
OCT
Optical Coherence Tomography of study eye.
Visual Acuity
Visual acuity measured by ETDRS

Locations

Country Name City State
United Kingdom Moorfields Eye Hospital NHS Foundation Trust, 162 City Road London

Sponsors (12)

Lead Sponsor Collaborator
Moorfields Eye Hospital NHS Foundation Trust Bradford Teaching Hospitals NHS Foundation Trust, Cardiff University, City, University of London, King's College London, Leeds Teaching Hospital NHS Foundation Trust, Manchester University NHS Foundation Trust, National Institute for Health Research, United Kingdom, Newcastle University, University College, London, University Hospitals Bristol and Weston NHS Foundation Trust, York Teaching Hospitals NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary The proportion of Participants who reactivate within 12 months of randomisation but are not identified as having re-activated (false negatives). The proportion of Participants who reactivate within 12 months of randomisation but are not identified as having re-activated (false negatives). 12 months
Primary Primary economic outcome: Incremental cost per quality adjusted life year (QALY) gained over the estimated patient lifetime estimated from an economic model informed by trial data. Primary economic outcome: Incremental cost per quality adjusted life year (QALY) gained over the estimated patient lifetime estimated from an economic model informed by trial data. 12 months
Secondary Diagnostic accuracy of the intervention (community optometry follow up of QnAMD) against the reference standard (rate of false negatives and false positives) Diagnostic accuracy of the intervention (community optometry follow up of QnAMD) against the reference standard (rate of false negatives and false positives) 12 months
Secondary Rate of over-referral (i.e. Reference Standard is quiescent but classification is 'reactivated' or 'suspicious') Rate of over-referral (i.e. Reference Standard is quiescent but classification is 'reactivated' or 'suspicious') 12 months
Secondary Mean change in visual acuity (measured with habitual correction and pinhole) for in the Participants intervention and control groups Mean change in visual acuity (measured with habitual correction and pinhole) for in the Participants intervention and control groups 12 months
Secondary Rate of 'suspicious' lesion classification in community care Rate of 'suspicious' lesion classification in community care 12 months
Secondary Rate of patient non-attendance and loss to follow up in secondary and primary care Rate of patient non-attendance and loss to follow up in secondary and primary care 12 months
Secondary Use of health services and patient costs collected via eCRF and participant completed questionnaires Use of health services and patient costs collected via eCRF and participant completed questionnaires 12 months
Secondary Costs of interventions and subsequent care to the NHS modelled over the estimated lifetime Costs of interventions and subsequent care to the NHS modelled over the estimated lifetime 12 months
Secondary Modelled estimates of visual impairment and QALYs based on responses to the EQ-5D-5L. Modelled estimates of visual impairment and QALYs based on responses to the EQ-5D-5L 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT01432847 - Cell Collection to Study Eye Diseases
Completed NCT00971464 - Low Vision Study Comparing EV Training vs. CCTV for AMD Rehabilitation Phase 2
Terminated NCT00332657 - Anecortave Acetate Risk Reduction Trial (AART) Phase 3
Recruiting NCT04796545 - Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration N/A
Completed NCT01766596 - Study the Signs of Ocular Degeneration in a Population Cohort (Dijon 3C Montrachet Cohort) N/A
Completed NCT03322930 - Rod Sensitivity in Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP)
Completed NCT01778491 - AMD Phenotype and Genotype Study
Completed NCT01016873 - INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD Phase 2
Active, not recruiting NCT03845582 - Phase 3 Study of ALK-001 in Geographic Atrophy Phase 3
Completed NCT03372746 - Generation of Induced Pluripotent Stem (iPS) Cell Lines From Skin Fibroblast Cells of Participants With Age-Related Macular Degeneration
Completed NCT03367767 - Age-Related Eye Disease Study 2 (AREDS2) 10-year Follow-On
Terminated NCT00333216 - Anecortave Acetate Risk-Reduction Trial (AART) Phase 3
Completed NCT01570790 - Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration Phase 1/Phase 2
Completed NCT00346866 - Anecortave Acetate Versus Placebo in AMD Patients Following PDT Phase 2
Withdrawn NCT00726466 - Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration Phase 1
Completed NCT00306488 - OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration Phase 2
Terminated NCT02348359 - X-82 to Treat Age-related Macular Degeneration Phase 2
Completed NCT01632527 - Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Age-Related Macular Degeneration (AMD) Phase 1/Phase 2
Withdrawn NCT01339949 - Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV) N/A
Recruiting NCT03675880 - TAB014(Drug Code) in Wet( Neovascular)Age-related Macular Degeneration(AMD) Subjects Phase 1